JP2011503012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011503012A5 JP2011503012A5 JP2010532342A JP2010532342A JP2011503012A5 JP 2011503012 A5 JP2011503012 A5 JP 2011503012A5 JP 2010532342 A JP2010532342 A JP 2010532342A JP 2010532342 A JP2010532342 A JP 2010532342A JP 2011503012 A5 JP2011503012 A5 JP 2011503012A5
- Authority
- JP
- Japan
- Prior art keywords
- histone
- inhibitor
- subject
- peptide
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010033040 Histones Proteins 0.000 claims description 72
- 239000003112 inhibitor Substances 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 54
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 48
- 230000003013 cytotoxicity Effects 0.000 claims description 34
- 231100000135 cytotoxicity Toxicity 0.000 claims description 34
- 239000012634 fragment Substances 0.000 claims description 24
- 230000002583 anti-histone Effects 0.000 claims description 20
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 230000001988 toxicity Effects 0.000 claims description 7
- 231100000419 toxicity Toxicity 0.000 claims description 7
- 241000283707 Capra Species 0.000 claims description 6
- 241000282693 Cercopithecidae Species 0.000 claims description 6
- 241000282326 Felis catus Species 0.000 claims description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 6
- 241001494479 Pecora Species 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 230000008733 trauma Effects 0.000 claims description 6
- 231100000433 cytotoxic Toxicity 0.000 claims description 5
- 230000001472 cytotoxic effect Effects 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 102000001398 Granzyme Human genes 0.000 claims description 4
- 108060005986 Granzyme Proteins 0.000 claims description 4
- 102000006947 Histones Human genes 0.000 claims description 4
- 101800004937 Protein C Proteins 0.000 claims description 4
- 101800001700 Saposin-D Proteins 0.000 claims description 4
- 102400000827 Saposin-D Human genes 0.000 claims description 4
- 230000000770 proinflammatory effect Effects 0.000 claims description 4
- 229960000856 protein c Drugs 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 241000193738 Bacillus anthracis Species 0.000 claims description 2
- 206010061818 Disease progression Diseases 0.000 claims description 2
- 238000002965 ELISA Methods 0.000 claims description 2
- 108010023321 Factor VII Proteins 0.000 claims description 2
- 108010088842 Fibrinolysin Proteins 0.000 claims description 2
- 206010058872 Fungal sepsis Diseases 0.000 claims description 2
- 208000032843 Hemorrhage Diseases 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 108090001007 Interleukin-8 Proteins 0.000 claims description 2
- 206010030113 Oedema Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
- 201000003229 acute pancreatitis Diseases 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 201000005008 bacterial sepsis Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000005796 circulatory shock Effects 0.000 claims description 2
- 230000016396 cytokine production Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 230000005750 disease progression Effects 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 210000002889 endothelial cell Anatomy 0.000 claims description 2
- 230000003511 endothelial effect Effects 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 2
- 230000035699 permeability Effects 0.000 claims description 2
- 229940012957 plasmin Drugs 0.000 claims description 2
- 238000004393 prognosis Methods 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000000451 tissue damage Effects 0.000 claims description 2
- 231100000827 tissue damage Toxicity 0.000 claims description 2
- 230000005747 tumor angiogenesis Effects 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 230000003213 activating effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98588607P | 2007-11-06 | 2007-11-06 | |
| PCT/US2008/082632 WO2009061918A1 (en) | 2007-11-06 | 2008-11-06 | Extracellular histones as biomarkers for prognosis and molecular targets for therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011503012A JP2011503012A (ja) | 2011-01-27 |
| JP2011503012A5 true JP2011503012A5 (enExample) | 2012-11-08 |
Family
ID=40270490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010532342A Pending JP2011503012A (ja) | 2007-11-06 | 2008-11-06 | 予後に関するバイオマーカーおよび治療の分子標的としての細胞外ヒストン |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US8716218B2 (enExample) |
| EP (1) | EP2209485B1 (enExample) |
| JP (1) | JP2011503012A (enExample) |
| AU (1) | AU2008323947B2 (enExample) |
| CA (1) | CA2704974C (enExample) |
| WO (1) | WO2009061918A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009061918A1 (en) | 2007-11-06 | 2009-05-14 | Oklahoma Medical Research Foundation | Extracellular histones as biomarkers for prognosis and molecular targets for therapy |
| ES2524669T3 (es) * | 2007-11-16 | 2014-12-10 | Biocartis Nv | Biomarcadores y procedimientos de diagnóstico, predicción y/o pronóstico de septicemia y usos de los mismos |
| US9701739B2 (en) | 2010-08-20 | 2017-07-11 | Josai University Corporation | Monoclonal antibody having immunosuppressive activity or antigen binding fragment thereof |
| JPWO2012067152A1 (ja) * | 2010-11-16 | 2014-05-12 | 三菱化学株式会社 | ＥｎｄｏｔｈｅｌｉａｌＰｒｏｔｅｉｎＣＲｅｃｅｐｔｏｒ蛋白質による脳梗塞の検査方法 |
| WO2012071611A1 (en) * | 2010-12-01 | 2012-06-07 | The Australian National University | Histone inhibition |
| TWI442934B (zh) * | 2011-03-11 | 2014-07-01 | Univ Taipei Medical | 組蛋白h4抗體的用途 |
| JP2015117181A (ja) * | 2012-02-22 | 2015-06-25 | 学校法人 城西大学 | 敗血症治療剤 |
| CA2898472C (en) | 2013-02-15 | 2023-03-07 | Immunomedics, Inc. | Chimeric and humanized anti-histone antibodies |
| JPWO2013125687A1 (ja) * | 2013-02-22 | 2015-07-30 | 学校法人 城西大学 | 炎症疾患治療剤 |
| FR3007411B1 (fr) * | 2013-06-21 | 2015-07-03 | Agronomique Inst Nat Rech | Anticorps monocatenaire a chaine lourde de camelide dirige contre la chromatine et utilisations |
| EP3160504B1 (en) | 2014-06-24 | 2020-09-16 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
| US10351621B2 (en) | 2014-06-24 | 2019-07-16 | Immunomedics, Inc. | Anti-histone therapy in acute kidney injury |
| PL3164123T3 (pl) * | 2014-07-02 | 2020-11-16 | Inflectis Bioscience | Nowe zastosowania terapeutycznych pochodnych benzylidenoguanidyny do leczenia proteopatii |
| US10633410B2 (en) | 2014-12-22 | 2020-04-28 | University Of Iowa Research Foundation | Nucleic acid aptamers to treat histone-induced disease states |
| US11391742B2 (en) | 2015-02-10 | 2022-07-19 | B.R.A.H.M.S. Gmbh | Free histone proteins as biomarkers |
| CN106611094B (zh) * | 2015-10-15 | 2021-08-06 | 北京寻因生物科技有限公司 | 基于肠道微生物菌群预测及干预化疗药物毒副反应的系统 |
| JP6738652B2 (ja) * | 2016-05-26 | 2020-08-12 | シスメックス株式会社 | 試料分析方法、試料分析装置および試薬 |
| CN109564226A (zh) * | 2016-08-09 | 2019-04-02 | B.R.A.H.M.S 有限公司 | 作为指示器官功能障碍的标志物的组蛋白和/或proADM |
| CA3033094A1 (en) | 2016-08-09 | 2018-02-15 | B.R.A.H.M.S Gmbh | Histones and/or proadm as markers indicating an adverse event |
| CN106397575A (zh) * | 2016-10-20 | 2017-02-15 | 上海懿贝瑞生物医药科技有限公司 | 一种具有胞外组蛋白毒性抑制作用的多肽制备方法及用途 |
| WO2018083308A1 (en) * | 2016-11-04 | 2018-05-11 | Centro De Investigación Biomédica En Red (Ciber-Isciii) | Mass spectrometry-based methods for the detection of circulating histones h3 and h2b in plasma from sepsis or septic shock (ss) patients |
| EP3577465B1 (en) | 2017-02-02 | 2023-03-29 | B.R.A.H.M.S GmbH | Proadm as marker indicating an adverse event |
| JP2020073459A (ja) * | 2017-03-06 | 2020-05-14 | 学校法人順天堂 | ヒストンによる細胞傷害を抑制するための薬剤 |
| AU2018332326B2 (en) | 2017-09-18 | 2025-04-03 | Santersus Ag | Method and device for purification of blood from circulating cell free DNA |
| GB201804833D0 (en) * | 2018-03-26 | 2018-05-09 | Univ Liverpool | Pro-coagulant histones |
| CN110101838B (zh) * | 2019-04-29 | 2022-07-01 | 陕西师范大学 | 一种提高组蛋白抗大肠杆菌性能的方法 |
| CN111202839A (zh) * | 2020-02-21 | 2020-05-29 | 佛山科学技术学院 | 一种组蛋白h4在抑制禽流感病毒中的应用 |
| US20230149453A1 (en) * | 2020-04-03 | 2023-05-18 | Medsenic | Use of an arsenic compound for treating a short or long cytokine storm in various autoimmune/inflammatory diseases in humans or animals |
| CN112679579B (zh) * | 2020-12-29 | 2022-02-01 | 潍坊医学院 | 一种分离自华蟾素注射液的镇痛肽ci5及其应用 |
| WO2023126672A1 (en) | 2021-12-27 | 2023-07-06 | Santersus Ag | Method and device for removal of circulating cell free dna |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000064466A1 (en) | 1999-04-28 | 2000-11-02 | Northwestern University | Localization of major peptide autoepitopes for nucleosome specific t cells of systemic lupus erythematosus |
| US7238656B2 (en) | 2001-08-29 | 2007-07-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Protective factors against inflammation, burns and noxious stimuli |
| US7528227B2 (en) | 2004-03-23 | 2009-05-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Histone H2A peptide derivatives and uses thereof |
| TW200407335A (en) * | 2002-07-22 | 2004-05-16 | Chugai Pharmaceutical Co Ltd | Non-neutralizing antibody to inhibit the inactivation of activated protein C |
| JP4834826B2 (ja) | 2003-07-22 | 2011-12-14 | 独立行政法人産業技術総合研究所 | ヒストンｈ３及びｈ４リンカー領域を認識するモノクローナル抗体及びその産生ハイブリドーマ |
| MXPA06014075A (es) * | 2004-06-03 | 2007-03-15 | Novimmune Sa | Anticuerpos anti-cd3 y metodos de uso de los mismos. |
| JP2007246473A (ja) * | 2006-03-17 | 2007-09-27 | Chemo Sero Therapeut Res Inst | 臓器障害抑制剤 |
| EP2011490A1 (en) | 2007-07-05 | 2009-01-07 | Sanofi-Aventis | Beta adrenergic receptor ligand derivatives for modulating apoptosis |
| WO2009061918A1 (en) * | 2007-11-06 | 2009-05-14 | Oklahoma Medical Research Foundation | Extracellular histones as biomarkers for prognosis and molecular targets for therapy |
-
2008
- 2008-11-06 WO PCT/US2008/082632 patent/WO2009061918A1/en not_active Ceased
- 2008-11-06 CA CA2704974A patent/CA2704974C/en active Active
- 2008-11-06 JP JP2010532342A patent/JP2011503012A/ja active Pending
- 2008-11-06 US US12/266,336 patent/US8716218B2/en active Active
- 2008-11-06 EP EP08847874.8A patent/EP2209485B1/en active Active
- 2008-11-06 AU AU2008323947A patent/AU2008323947B2/en active Active
-
2014
- 2014-05-06 US US14/270,470 patent/US10238711B2/en active Active
-
2015
- 2015-06-09 US US14/734,238 patent/US10350261B2/en active Active
-
2017
- 2017-12-12 US US15/838,639 patent/US20180092961A1/en not_active Abandoned
-
2019
- 2019-01-31 US US16/263,124 patent/US11458187B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011503012A5 (enExample) | ||
| Qadri et al. | Kinin B1 receptors as a therapeutic target for inflammation | |
| Eich et al. | A randomized, placebo-controlled phase 2 trial of CNTO 6785 in chronic obstructive pulmonary disease | |
| De Souza et al. | HMGB1 in vascular diseases: its role in vascular inflammation and atherosclerosis | |
| Park et al. | Adiponectin as an anti-fibrotic and anti-inflammatory adipokine in the liver | |
| Chiu et al. | IL-20 and IL-20R1 antibodies protect against liver fibrosis | |
| Iyer et al. | Early matrix metalloproteinase-9 inhibition post-myocardial infarction worsens cardiac dysfunction by delaying inflammation resolution | |
| JP2010500360A5 (enExample) | ||
| US9981012B2 (en) | Compositions and methods for protecting the kidney from ischemia reperfusion injury | |
| Bongoni et al. | Complement-mediated damage to the glycocalyx plays a role in renal ischemia-reperfusion injury in mice | |
| JP2011500843A5 (enExample) | ||
| JP2017113019A5 (enExample) | ||
| Zhu et al. | Activation of angiotensin II type 2 receptor suppresses TNF-α-induced ICAM-1 via NF-кB: possible role of ACE2 | |
| NZ596409A (en) | Anti macrophage migration inhibitory factor antibodies | |
| JP2020507587A5 (enExample) | ||
| EP2552954A1 (en) | Factor xii inhibitors for treating interstitial lung disease | |
| CA2925087C (en) | Peptides inhibiting cold-inducible rna binding protein activity | |
| Dsouza et al. | Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis | |
| JP2023052614A (ja) | うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場 | |
| JP2021505611A5 (enExample) | ||
| JP2015511625A5 (enExample) | ||
| Linders et al. | Complement component 3 is required for tissue damage, neutrophil infiltration, and ensuring NET formation in acute pancreatitis | |
| Tsao et al. | Expression of high-mobility group box protein 1 in diabetic foot atherogenesis | |
| Wang et al. | Simultaneous targeting of oxidative stress and fibrosis reverses cardiomyopathy‐induced ventricular remodelling and dysfunction | |
| Elfeky et al. | Adiponectin suppression of late inflammatory mediator, HMGB1-induced cytokine expression in RAW264 macrophage cells |